Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)

Launched by BENEDITO MAURO ROSSI · Apr 22, 2025

Keywords

ClinConnect Summary

The clinical trial titled "Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer" (mirPANC 2) is looking at how we can improve the way we monitor treatment for pancreatic cancer that has spread to other parts of the body. The study focuses on small molecules in the blood called miRNAs, which may help doctors determine if a treatment is working effectively or if changes are needed. This approach aims to make monitoring less invasive—meaning fewer procedures for patients—and more tailored, allowing for more personalized and effective treatment plans.

To participate in this trial, you must be at least 18 years old and have been diagnosed with metastatic pancreatic cancer. You should also be starting a specific treatment called FOLFIRINOX. However, if you’ve had previous chemotherapy or do not meet certain health criteria, you may not be eligible. If you decide to join the study, you can expect to provide blood samples at different times to help researchers understand how well the treatment is working. This trial is currently recruiting participants, and your involvement could contribute to better treatment strategies for pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with metastatic PDAC;
• • Patients who will start treatment with FOLFIRINOX;
• • 18 years or older;
• • Who agree to participate in the study by signing the Informed Consent Form;
• Exclusion Criteria:
• • Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
• • Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;